now? so let s be real clear about one thing, there is no actual crisis here. this is entirely a crisis of their making if it occurs. president joe biden continues to call out house republicans over the debt ceiling, delivering, what sure sounded like a 2024 stump speech. meanwhile on capitol hill republican senators air their grievances with the attorney general. and also ahead, a major move on the price of insulin that will bring much needed relief for millions of americans. good morning and welcome to way too early on this thursday, march 2nd. i m jonathan lemire, thanks for starting your day with us. we ll begin on capitol hill where attorney general merrick garland faced a barrage of attacks from republican lawmakers yesterday during a senate judiciary committee hearing. as is customary for an attorney general to do, garland appeared before the new congress to answer questions about a wide range of topics. but the a.g. spent a large portion of the four-hour hearing de
tornados tear through texas and louisiana, right now more than 60 million people are still under the threat of severe storms. ammunition on the agenda today. president biden meeting the german chancellor and sending more firepower to ukraine. it is friday, welcome to our viewers in the united states and around the world. i m christine romans. just hours from now, tau alex murdaugh will stand in a courtroom to learn his fate. a judge will issentence him for murdering his own wife and son. guilty verdict. verdict guilty. verdict guilty. verdict guilty. the jury heard six weeks of testimony but took less than three hours to convict him. murdaugh now facing a possible 30 years behind bars. justice was done today. it doesn t matter who your family is, it doesn t matter how much money you have or people think you have. it doesn t matter what you think how prominent you are, if you do wrong, if you break the law, if you murder, then justice will be done in south carolina.
CAMBRIDGE, Mass., June 01, 2024 Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in.
Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer